Core Viewpoint - Tianzhihang (688277) is actively pursuing an overseas expansion strategy, showcasing its technological innovations and product offerings at international exhibitions, and has achieved CE certification for its orthopedic surgical navigation system, laying the groundwork for entering overseas markets [1][3]. Group 1: Company Performance - As of October 17, 2025, Tianzhihang's stock closed at 17.53 yuan, down 2.77% from the previous week [1]. - The company has maintained the largest market share in the domestic orthopedic robot market, with a significant increase in bidding activity, showing over 50% year-on-year growth in orthopedic robot tenders [1][3]. Group 2: Technological Advancements - Since 2006, the company has been a pioneer in remote orthopedic robotic surgery, completing over 1,000 remote surgeries across 24 provinces and municipalities, establishing 5G remote surgery as a standard practice [2][3]. - The company has received approval for robotic-assisted orthopedic surgery in over 20 provinces and cities, with Beijing including it in its medical insurance payment directory [2][3]. Group 3: Corporate Governance - The second extraordinary general meeting of shareholders was held on October 16, 2025, with 203 shareholders present, representing 36.03% of the voting shares [3][4]. - The meeting approved the increase of the estimated amount for daily related transactions and the re-election of a non-independent director, with no proposals being rejected [3][4].